Trial reportJournal of acquired immune deficiency syndromes (1999)2016
Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection.
Trial report in Journal of acquired immune deficiency syndromes (1999), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03701802 (Immunogenetic Modulators of Mucosal Protection From HIV-1), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunogenetic Modulators of Mucosal Protection From HIV-1: The Kinga Study
Who cites it
11 citing papers in PubMed.
- Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women.AIDS (London, England) · 2019Trial
- NK cell activation and CD4+ T cell α4β7 expression are associated with susceptibility to HIV-1.The Journal of clinical investigation · 2025Article
- Observational
- Article
- Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice.PLoS pathogens · 2021Article
- Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection.bioRxiv : the preprint server for biology · 2020Article
- HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.Blood · 2020Article
- Immune Predictors of Mortality After Ribonucleic Acid Virus Infection.The Journal of infectious diseases · 2020Article
- Impact of Endemic Infections on HIV Susceptibility in Sub-Saharan Africa.Tropical diseases, travel medicine and vaccines · 2019Review
- Extensive Homeostatic T Cell Phenotypic Variation within the Collaborative Cross.Cell reports · 2017Article
- Human Immunodeficiency Virus Proteins Mimic Human T Cell Receptors Inducing Cross-Reactive Antibodies.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTwo distinct hypotheses have been proposed for T-cell involvement in protection from HIV-1 acquisition. First, HIV-1-specific memory T-cell responses generated on HIV-1 exposure could mount an efficient response to HIV-1 and inhibit the establishment of an infection. Second, a lower level of immune activation could reduce the numbers of activated, HIV-1-susceptible CD4 T cells, thereby diminishing the likelihood of infection.
methodsTo test these hypotheses, we conducted a prospective study among high-risk heterosexual men and women, and tested peripheral blood samples from individuals who subsequently acquired HIV-1 during follow-up (cases) and from a subset of those who remained HIV-1 uninfected (controls).
resultsWe found no difference in HIV-1-specific immune responses between cases and controls, but Treg frequency was higher in controls as compared with cases and was negatively associated with frequency of effector memory CD4 T cells.
conclusionsOur findings support the hypothesis that low immune activation assists in protection from HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.